CANSINOBIO Achieves First Patient Enrollment for Combined DTcP-Hib-MCV4 Vaccine
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 19 2025
0mins
Source: aastocks
Clinical Trial Initiation: CANSINOBIO has officially started a Phase I clinical trial for its DTcP-Hib-MCV4 Combined Vaccine, with the first patient enrolled.
Target Age Group: The trial aims to evaluate the safety and immunogenicity of the vaccine in children aged 2 months to 6 years.
Analyst Views on 06185
Wall Street analysts forecast 06185 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 06185 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 38.780
Low
Averages
High
Current: 38.780
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
